cisatracurium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
neuromuscular blocking agents with rigid structure	661	96946-42-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cisatracurium besylate cisatracurium besilate cisatracurium	Molecular weight: 929.16 Formula: C53H72N2O12 CLOGP: 3.30 LIPINSKI: 2 HAC: 14 HDO: 0 TPSA: 126.44 ALOGS: -7.63 ROTB: 26 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cisatracurium besylate
cisatracurium besilate
cisatracurium

Molecular weight: 929.16
Formula: C53H72N2O12
CLOGP: 3.30
LIPINSKI: 2
HAC: 14
HDO: 0
TPSA: 126.44
ALOGS: -7.63
ROTB: 26

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	8.50 %	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	5.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.65 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
fu (Fraction unbound in plasma)	0.62 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.42 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.14 L/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	0	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 15, 1995	FDA	ABBVIE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	373.41	44.55	104	2812	23529	63462577
Anaphylactic reaction	144.05	44.55	67	2849	66033	63420073
Hypotension	99.09	44.55	89	2827	272515	63213591
Mixed liver injury	98.71	44.55	26	2890	4709	63481397
Bronchospasm	98.52	44.55	35	2881	17245	63468861
Cardiac arrest	98.33	44.55	58	2858	92487	63393619
Circulatory collapse	76.38	44.55	31	2885	21907	63464199
Myoclonus	75.02	44.55	28	2888	15840	63470266
Multiple organ dysfunction syndrome	74.84	44.55	41	2875	56711	63429395
Cardiogenic shock	71.69	44.55	28	2888	17904	63468202

Showing 1 to 10 of 18 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	287.00	34.56	91	3138	15850	34937852
Hyperthermia malignant	177.48	34.56	41	3188	2136	34951566
Anaphylactic reaction	126.59	34.56	61	3168	32240	34921462
Hypertransaminasaemia	113.17	34.56	35	3194	5571	34948131
Drug reaction with eosinophilia and systemic symptoms	101.77	34.56	53	3176	32959	34920743
Rhabdomyolysis	98.31	34.56	67	3162	68096	34885606
Toxic epidermal necrolysis	94.29	34.56	44	3185	21602	34932100
Bronchospasm	76.86	34.56	31	3198	10700	34943002
Shock	66.49	34.56	36	3193	24143	34929559
Hypotension	55.69	34.56	84	3145	221565	34732137

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	632.89	30.39	191	5645	35805	79702747
Anaphylactic reaction	253.21	30.39	123	5713	83620	79654932
Hyperthermia malignant	196.18	30.39	45	5791	2872	79735680
Bronchospasm	169.60	30.39	65	5771	24794	79713758
Hypotension	133.30	30.39	162	5674	440155	79298397
Cardiac arrest	128.87	30.39	104	5732	171992	79566560
Mixed liver injury	119.09	30.39	37	5799	7541	79731011
Hypertransaminasaemia	106.40	30.39	38	5798	11886	79726666
Shock	105.07	30.39	55	5781	43493	79695059
Toxic epidermal necrolysis	101.03	30.39	54	5782	44527	79694025

Showing 1 to 10 of 39 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	M03AC11	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Other quaternary ammonium compounds
CHEBI has role	CHEBI:48878	nicotinic antagonists
CHEBI has role	CHEBI:51371	muscle relaxants
FDA EPC	N0000175720	Nondepolarizing Neuromuscular Blocker
FDA PE	N0000175732	Neuromuscular Nondepolarizing Blockade
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D009466	Neuromuscular Blocking Agents
MeSH PA	D018373	Peripheral Nervous System Agents

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Muscle relaxation, function	indication	11977004
General anesthesia	indication	50697003
Skeletal Muscle Relaxation for Endotracheal Intubation	indication
Disorder of lung	contraindication	19829001	DOID:850
Myasthenia gravis	contraindication	91637004	DOID:437
Disorder of electrolytes	contraindication	237840007
Malignant hyperthermia	contraindication	405501007

Showing 1 to 7 of 7 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Acetylcholine receptor	Ion channel	P02708 P11230 Q07001	ACHA_HUMAN ACHB_HUMAN ACHD_HUMAN	ANTAGONIST	IC50	8		WOMBAT-PK	CHEMBL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
005186	NDDF
005213	NDDF
108452005	SNOMEDCT_US
108453000	SNOMEDCT_US
136561	RXNORM
192613	MMSL
36562	MMSL
372495006	SNOMEDCT_US
4020957	VUID
4020957	VANDF

Showing 1 to 10 of 25 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9396	INJECTION	2 mg	INTRAVENOUS	ANDA	29 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1098	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1098	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1098	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1103	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1103	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1103	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1208	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1208	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections
Cisatracurium Besylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1208	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next